910 results match your criteria Asia-Pacific Journal of Clinical Oncology [Journal]


The diameter of metastasis in positive sentinel lymph node biopsy affects axillary tumor load in early breast cancer.

Asia Pac J Clin Oncol 2019 Feb 13. Epub 2019 Feb 13.

Pathology Department, West Pomeranian Oncology Center, Szczecin, Poland.

Introduction: Omission of axillary lymph node dissection (ALND) after positive sentinel lymph biopsy (SLNB) has become a standard procedure for breast cancer patients with one or two metastatic lymph nodes. Here the aim was model development for selection for ALND.

Material And Methods: We analyzed 323 positive SLNB breast cancer patients, who afterwards underwent ALND. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13113DOI Listing
February 2019

Right versus left sided metastatic colorectal cancer: Teasing out clinicopathologic drivers of disparity in survival.

Asia Pac J Clin Oncol 2019 Feb 13. Epub 2019 Feb 13.

Footscray Hospital, Western Health, Footscray, Victoria, Australia.

Background: Metastatic colorectal cancer (mCRC) patients with a right-sided primary (RC) have an inferior survival to mCRC arising from a left-sided primary (LC). Previous analyses have suggested multiple factors contribute.

Methods: The Treatment of Recurrent and Advanced Colorectal Cancer (TRACC) Registry prospectively captured data on consecutive mCRC patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13135DOI Listing
February 2019
1 Read
1.058 Impact Factor

Translation and psychometric testing of Cancer Survivors' Unmet Needs, Chinese version.

Asia Pac J Clin Oncol 2019 Feb 13. Epub 2019 Feb 13.

School of Nursing, Queensland University of Technology, Brisbane, Queensland, Australia.

Aim: The aim of the study was to translate the Cancer Survivors' Unmet Needs (CaSUN) scale into Chinese, and then test its psychometric properties, for cancer survivors in Hong Kong.

Methods: The original questionnaire was translated from English into traditional Chinese (CaSUN-Chi), following standardized procedures. An expert panel was invited to assess the items' content validity, and pilot test on 15 patients to evaluate its readability. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13137DOI Listing
February 2019
1.058 Impact Factor

Association of hormone replacement therapy with increased risk of meningioma in women: A hospital-based multicenter study with propensity score matching.

Asia Pac J Clin Oncol 2019 Feb 13. Epub 2019 Feb 13.

Centre of Systems Medicine, Chinese Academy of Medical Sciences, Beijing, China.

Aim: There is no consensus regarding the association between hormone replacement therapy (HRT) and risk of meningioma so far. We conducted the first study among Chinese female patients to investigate the influence of HRT use on the risk of meningioma.

Methods: We retrospectively collected records of diagnosis of meningioma for women aged 50 years and above during 2011-2016 and dispense of HRT prior to meningioma diagnosis in three tertiary hospitals in China. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ajco.13138
Publisher Site
http://dx.doi.org/10.1111/ajco.13138DOI Listing
February 2019
4 Reads

Patterns of follow-up care after curative radiotherapy ± chemotherapy for stage I-III non-small cell lung cancer.

Asia Pac J Clin Oncol 2019 Feb 13. Epub 2019 Feb 13.

South Western Sydney Clinical School, University of NSW, NSW, Australia.

Objectives: To describe patterns of follow-up care for non-small cell lung cancer patients treated with curative radiotherapy and to evaluate the role of routine imaging.

Materials And Methods: We retrospectively analyzed follow-up care of patients with stage I-III non-small cell lung cancer treated with curative radiotherapy (minimum dose of 50 Gy) between 2007 and 2011 at three Sydney institutions. Patient demographics, tumor characteristics and treatment factors were collected from oncology and hospital records. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13127DOI Listing
February 2019
1 Read

First-line therapy for metastatic colorectal cancer: Current perspectives and future directions.

Asia Pac J Clin Oncol 2019 Feb;15 Suppl 1:3-14

Department of Cancer Care Services, Royal Brisbane Hospital, University Of Queensland, Herston, Queensland.

The prognosis for patients with newly diagnosed inoperable metastatic colorectal cancer has steadily improved over the past two decades as new agents have been introduced into clinical practice and many new biomarkers have been discovered. In parallel with this progress, clinicians face increasingly complex treatment decisions. This review summarizes recent progress, with a historical perspective, which should help guide the clinician in decision making and optimal therapy selection. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ajco.13119
Publisher Site
http://dx.doi.org/10.1111/ajco.13119DOI Listing
February 2019
1 Read
1.058 Impact Factor

Registry-based randomized clinical trials as a method to improve cancer care in Australia.

Asia Pac J Clin Oncol 2019 Feb 12. Epub 2019 Feb 12.

Systems Biology and Personalised Medicine Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13122DOI Listing
February 2019
1.058 Impact Factor

Embracing the full spectrum of real-world data for cancer medicines research in Australia.

Asia Pac J Clin Oncol 2019 Feb 12. Epub 2019 Feb 12.

Centre for Big Data Research in Health, University of New South Wales, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ajco.13121
Publisher Site
http://dx.doi.org/10.1111/ajco.13121DOI Listing
February 2019
1 Read

What contributes to resilience in cancer patients? A principal component analysis of the Connor-Davidson Resilience Scale.

Asia Pac J Clin Oncol 2019 Feb 11. Epub 2019 Feb 11.

Flinders Centre for Innovation in Cancer, Flinders Medical Centre, and Flinders University, Adelaide, South Australia, Australia.

Purpose: Research suggests resilience is a complex multifactorial construct, which may improve health outcomes in cancer, but significant controversy exists regarding its definition and measurement. This study aimed to determine the components of resilience and their relative weight, as measured by the Connor-Davidson Resilience Scale in cancer patients.

Methods: As part of a larger study, a questionnaire including the Connor-Davidson Resilience Scale was distributed to 228 cancer patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13128DOI Listing
February 2019
1.058 Impact Factor

Association between human papillomavirus infection and prostate cancer: A global systematic review and meta-analysis.

Asia Pac J Clin Oncol 2019 Feb 10. Epub 2019 Feb 10.

Department of Virology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Although an increasing number of studies have been conducted to evaluate the association between human papillomavirus (HPV) infections and distribution of HPV types worldwide with the risk of prostate cancer (PC), the results remain inadequate. Hence, we investigated the association between HPV infection and PC risk using a meta-analysis. Relevant studies from January 1990 to December 2016 were searched in PubMed, Web of sciences, and Scopus databases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13124DOI Listing
February 2019

Significance of methylation status of MASPIN gene and its protein expression in prognosis of gallbladder cancer.

Asia Pac J Clin Oncol 2019 Feb 10. Epub 2019 Feb 10.

Department of Orthopaedic Surgery, King George's Medical University, Lucknow, India.

Aim: We investigated prognostic significance of methylation status of MASPIN gene and its protein expression in normal subjects, cholelithiasis and gallbladder cancer (GBC) patients.

Methods: MASPIN protein expression and its promoter methylation in gallbladder tissue of cholelithiasis (n = 36), GBC (n = 46) and controls (n = 25) were investigated. Clinicopathological parameters and prognosis of patients with GBC were correlated with protein expression of MASPIN. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13129DOI Listing
February 2019
1 Read
1.058 Impact Factor

Androgen deprivation therapy in nonmetastatic prostate cancer patients: Indications, treatment effects, and new predictive biomarkers.

Asia Pac J Clin Oncol 2019 Feb 6. Epub 2019 Feb 6.

Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center of China, Beijing, China.

Men with prostate cancer with positive margins, extraprostatic extension, positive lymph nodes, high prostate-specific antigen, or high Gleason Score are at high risk of recurrence following primary therapy. Androgen deprivation therapy (ADT), which includes medical/surgical castration, antiandrogen therapy, and combined androgen blockade, can be combined with primary therapy to shrink the tumor, reduce margin positivity, and reduce the risk of recurrence. However, many problems still remain, such as optimizing the application of ADT in the treatment of prostate cancer, for example, ideal patient population and optimal timing and duration of therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13108DOI Listing
February 2019
1 Read

Reply to M. Alexander et al.

Asia Pac J Clin Oncol 2019 Feb 3. Epub 2019 Feb 3.

Section of Thrombosis & Benign Hematology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13098DOI Listing
February 2019
1.058 Impact Factor

Timing of brain metastases development in metastatic renal cell cancer patients treated with targeted therapies and survival outcomes: An Australian multicenter study.

Asia Pac J Clin Oncol 2019 Jan 30. Epub 2019 Jan 30.

Olivia Newton-John Cancer Wellness & Research Centre, Austin Hospital, Melbourne, Victoria, Australia.

Aim: Targeted therapy (TT) has improved survival for metastatic renal cell carcinoma (mRCC). However, survival is usually limited if brain metastases (BMs) develop. We aimed to evaluate survival outcomes in mRCC patients based on timing of BM diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13109DOI Listing
January 2019
3 Reads

Hurdles in radiation planning for glioblastoma: Can delayed-contrast enhanced computed tomography be a potential solution?

Asia Pac J Clin Oncol 2019 Jan 30. Epub 2019 Jan 30.

Department of Radiotherapy, PGIMER, Chandigarh, India.

Objective: Conformal radiation is the standard of care in treatment of glioblastoma. Although co-registration of magnetic resonance imaging (MRI) with early contrast enhanced computed tomography (CECT) is recommended for target delineation by consensus guidelines, ground realities in developing countries often result in availability of less-than-ideal MR sequences for treatment planning. Purpose of this study is to analyze the impact of incorporation of delayed-CECT sequences for radiation planning in glioblastomas, as an adjunct or alternative to MRI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13111DOI Listing
January 2019

Clinical efficacy of concurrent bevacizumab for malignant ascites in nonsquamous cell carcinoma of the lung.

Asia Pac J Clin Oncol 2019 Jan 29. Epub 2019 Jan 29.

Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.

Purpose: Lung cancer with malignant peritoneal carcinomatosis and malignant ascites is rare, often indicates the terminal stage, and is refractory to treatment. The median survival time of lung cancer patients with malignant ascites has been reported to be as short as 15 days to 2 months in retrospective studies.

Methods: We reviewed all lung cancer patients who had cytologically or pathologically proven malignant ascites and received aggressive therapy including chemotherapy, anti-angiogenesis agents and target therapy at a Taiwan hospital from January 2015 to December 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13131DOI Listing
January 2019
1 Read

Outcome of chemotherapy with or without targeted agents in metastatic colorectal cancer patients with deficient DNA mismatch repair: A single center, cohort study.

Asia Pac J Clin Oncol 2019 Jan 29. Epub 2019 Jan 29.

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Aims: Metastatic colorectal cancer (mCRC) with deficient DNA mismatch repair (dMMR) is a rare disease accounting only for 4-5% of the whole mCRC and its optimal treatment still remains unclear. We conducted a retrospective study to evaluate the outcome of chemotherapy with or without bevacizumab or cetuximab in this setting.

Methods: A total of 729 colorectal cancer patients with dMMR status were screened for eligibility. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13130DOI Listing
January 2019
1.058 Impact Factor

Association of APOBEC3 deletion with cancer risk: A meta-analysis of 26 225 cases and 37 201 controls.

Asia Pac J Clin Oncol 2019 Jan 29. Epub 2019 Jan 29.

Department of Genetics, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.

Previous studies have found inconsistent results regarding gene deletion in APOBEC3 (apolipoprotein B mRNA-editing catalytic polypeptide-like 3) and risk of cancer. We conducted a meta-analysis of all eligible case-control studies to find out the associations between APOBEC3 deletion and cancer risk by pooling the odds ratios (ORs) and corresponding 95% confidence intervals (CIs). Overall, the findings from 20 studies (13 articles) involving of a total of 26 225 cases and 37 201 controls revealed that DD genotype was associated significantly with increased cancer risk compared to II genotype (OR = 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13107DOI Listing
January 2019

Preoperative C-reactive protein to albumin ratio is a predictor of survival after pancreatic resection for pancreatic ductal adenocarcinoma.

Asia Pac J Clin Oncol 2019 Jan 10. Epub 2019 Jan 10.

Department of Surgery, Meiwa Hospital, Hyogo, Japan.

Aim: Systemic inflammation and nutritional status are associated with clinical outcomes of cancer patients. We investigated the prognostic value of preoperative C-reactive protein to albumin ratio (CAR) in patients with pancreatic ductal adenocarcinoma (PDA) after pancreatic resection.

Methods: One-hundred and thirty-six PDA patients who underwent pancreatic resection between January 2005 and June 2017 were retrospectively enrolled. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13123DOI Listing
January 2019
1 Read

The value of magnetic resonance imaging in esophageal carcinoma: Tool or toy?

Asia Pac J Clin Oncol 2019 Jan 4. Epub 2019 Jan 4.

Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, Shandong Province, China.

Currently, the use of magnetic resonance imaging (MRI) in patients with esophageal carcinoma is limited. However, the quality of MRI for esophageal carcinoma continues to improve and the importance of MRI in patients with esophageal carcinoma has been gradually recognized. Compared with endoscopic ultrasound and computed tomography applied in T and N staging, MRI has now achieved excellent results after the imaging technique has been optimized. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13112DOI Listing
January 2019
2 Reads

Impact of modified FOLFOX-6 for patients with gastric cancer and a gastrointestinal obstruction.

Asia Pac J Clin Oncol 2018 Dec 13. Epub 2018 Dec 13.

Department of Internal Medicine II, Osaka Medical College, Takatsuki, Osaka, Japan.

Aim: Gastric cancer patients are normally treated with oral fluoropyrimidine and cisplatin or oxaliplatin; however, treating patients who also have a gastrointestinal obstruction is often difficult because of their poor oral intake. Instead, a modified (m)FOLFOX-6 regimen is administered, even to patients with gastrointestinal obstructions. The aim of this study was to assess the efficacy of mFOLFOX-6 for gastric cancer patients with a gastrointestinal obstruction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13110DOI Listing
December 2018
1 Read

A clinical trial with protracted infusion 5-fluorouracil and mitomycin C for localized squamous cell carcinoma of the anus.

Asia Pac J Clin Oncol 2019 Feb 9;15(1):75-81. Epub 2018 Dec 9.

Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

Purpose: Mitomycin C (MMC) plus standard 5-fluorouracil (FU) infusion in weeks 1 and 5 often contributes to radiotherapy interruptions and possibly less-than-ideal outcomes in anal cancer. This study was to evaluate alternative strategies for chemotherapy delivery that might be less toxic or more efficacious, and outcomes of patient-initiated treatment interruption for severe acute toxicity.

Materials And Methods: This was a prospective, nonrandomized study for patients with T1-4N0-3M0 anal squamous carcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13106DOI Listing
February 2019
10 Reads

The effects of switching EGFR-TKI treatments for non-small cell lung cancer because of adverse events.

Asia Pac J Clin Oncol 2018 Dec 2. Epub 2018 Dec 2.

Division of Respiratory Medicine, Saiseikai Kumamoto Hospital, Kumamoto, Japan.

Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are used to treat patients with non-small cell lung cancer (NSCLC) and EGFR driver mutations. Although some patients discontinued these treatments because of adverse events, it is unclear whether switching EGFR-TKI because of adverse events provides a benefit.

Methods: This retrospective study evaluated data from 22 patients with EGFR mutation-positive NSCLC who received at least two EGFR-TKIs that were switched because of adverse events (March 2011 to September 2017). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13103DOI Listing
December 2018
1 Read

Adjuvant therapy after nephrectomy for renal cell carcinoma.

Authors:
Alain Ravaud

Asia Pac J Clin Oncol 2018 Nov;14 Suppl 5:33-36

Department of Medical Oncology, Hôpital Saint-André, Bordeaux, France.

Adjuvant treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitor in renal cell carcinoma after nephrectomy has been reported through three clinical trials: S-TRAC, ASSURE and PROTECT. Only S-TRAC has been significantly positive on primary end-point disease-free survival under sunitinib compared to placebo, whereas ASSURE and PROTECT did not show any gain under sunitinib, sorafenib or pazopanib. This short review presents the differences between the trials and provides hypotheses on why S-TRAC may have been positive. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ajco.13056
Publisher Site
http://dx.doi.org/10.1111/ajco.13056DOI Listing
November 2018
10 Reads

Advanced prostate cancer update 2018.

Authors:
Oliver Sartor

Asia Pac J Clin Oncol 2018 Nov;14 Suppl 5:9-12

Tulane Cancer Center, New Orleans, LA, USA.

The management of advanced prostate cancer today follows a multidisciplinary approach and involves multi-target treatments. The paradigm has shifted from traditional hormonal therapy, surgery and radiation, to the use of chemotherapy, and until recently the development of various immunotherapies and radiopharmaceuticals. Recent advances turn to molecular medicine combining the expertise of molecular pathology and genetics. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ajco.13057
Publisher Site
http://dx.doi.org/10.1111/ajco.13057DOI Listing
November 2018
18 Reads

Editorial.

Authors:

Asia Pac J Clin Oncol 2018 Nov;14 Suppl 5

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13105DOI Listing
November 2018
1 Read

Chemohormonal therapy for metastatic hormone-sensitive prostate cancer: An Asian perspective.

Asia Pac J Clin Oncol 2018 Nov;14 Suppl 5:5-8

Department of Clinical Oncology, State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong.

The treatment of metastatic hormone-sensitive prostate cancer (mHSPC) has been rapidly evolving. In the past, the use of chemotherapy was reserved for metastatic prostate cancer patients who developed castration resistance. Subsequently, there were three well-designed randomized controlled trials investigating the use of chemotherapy together with androgen deprivation therapy as the first-line treatment for metastatic hormone-sensitive prostate cancer. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ajco.13060
Publisher Site
http://dx.doi.org/10.1111/ajco.13060DOI Listing
November 2018
10 Reads

Evaluating radium-223 response in metastatic castration-resistant prostate cancer with imaging.

Authors:
Junpei Iizuka

Asia Pac J Clin Oncol 2018 Nov;14 Suppl 5:16-23

Department of Urology, Tokyo Women's Medical University, Tokyo, Japan.

Radium-223 is a first-in-class targeted alpha therapy indicated for treating bone metastases from metastatic castration-resistant prostate cancer (mCRPC) without visceral metastases. Imaging plays an important role in the selection of patients eligible for radium-223 therapy. In the ALSYMPCA trial protocol, bone scintigraphy was used to detect lesions, essentially osteoblastic bone metastases, whereas computed tomography (CT) was used to exclude visceral metastases, with no interim imaging until treatment completion unless clinically indicated. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ajco.13058
Publisher Site
http://dx.doi.org/10.1111/ajco.13058DOI Listing
November 2018
16 Reads

Revisiting the role of bone-modifying agents in the management of metastatic prostate cancer.

Authors:
Foon-Yiu Cheung

Asia Pac J Clin Oncol 2018 Nov;14 Suppl 5:13-15

Hong Kong Integrated Oncology Centre, Central, Hong Kong.

Bone metastases are a hallmark of advanced prostate cancer and may drive the morbidity and mortality of the disease in patients with a poor prognosis. The pathogenesis of bone metastasis involves the interaction between cancer cells, normal bone cells and the bone microenvironment. Targeting the bone microenvironment has become a promising therapy for patients with advanced prostate cancer and bone metastasis. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ajco.13061
Publisher Site
http://dx.doi.org/10.1111/ajco.13061DOI Listing
November 2018
10 Reads

Prime time for immunotherapy in advanced urothelial cancer.

Asia Pac J Clin Oncol 2018 Nov;14 Suppl 5:24-32

Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario.

Background: Metastatic urothelial cancer (UC) is a lethal disease. Until 2016, cytotoxic chemotherapy with substantial toxicity was the only therapeutic option. In the first-line metastatic setting, cisplatin-based combination chemotherapy remains the standard of care. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13059DOI Listing
November 2018
2 Reads

Practical considerations for clinicians for transitioning patients on maintenance therapy with olaparib capsules to the tablet formulation of olaparib.

Asia Pac J Clin Oncol 2018 Dec 26;14(6):459-464. Epub 2018 Nov 26.

Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

Purpose: Olaparib was originally formulated as 50 mg capsules with a recommended dose of 400 mg twice daily which requires patients to take 16 capsules a day. More recently, a tablet formulation with equivalent efficacy has become available and reduces the pill burden for patients to two tablets twice daily which is more convenient for patients. However, it is important to understand the key differences between the olaparib capsule and tablet formulations as they are not bioequivalent, and the doses are not interchangeable. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13104DOI Listing
December 2018
1 Read

Receipt of radiotherapy after mastectomy in women with breast cancer: Population-based cohort study in New Zealand.

Asia Pac J Clin Oncol 2018 Nov 15. Epub 2018 Nov 15.

Waikato Clinical Campus, University of Auckland, Hamilton, New Zealand.

Purpose: To investigate the receipt of postmastectomy radiotherapy (PMRT) in breast cancer patients in New Zealand for whom radiotherapy is strongly recommended in current clinical guidelines.

Method: This study involved all women who were diagnosed with primary invasive breast cancer in two health regions, had undergone a mastectomy, and met the "strong recommendation" criteria for PMRT based on New Zealand National Guidelines. We performed logistic regression analyses to identify demographic and clinical factors associated with the receipt of PMRT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13101DOI Listing
November 2018
2 Reads

The potential "additive" thromboembolic risk of radiotherapy.

Asia Pac J Clin Oncol 2018 Nov 13. Epub 2018 Nov 13.

Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ajco.13099
Publisher Site
http://dx.doi.org/10.1111/ajco.13099DOI Listing
November 2018
11 Reads

Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma.

Asia Pac J Clin Oncol 2019 Feb 13;15(1):26-30. Epub 2018 Nov 13.

Department of Medical Oncology, Canberra Region Cancer Centre, The Canberra Hospital, ACT, Australia.

Background: There is limited real-world data on the efficacy and safety of combination programmed cell death protein-1 (PD-1) inhibitor, nivolumab and the cytotoxic T-lymphocyte antigen (CTLA-4) inhibitor ipilimumab.

Method: We retrospectively identified patients (pts) with metastatic melanoma treated with three-weekly nivolumab (1 mg/kg) in combination with ipilimumab (3 mg/kg) for four cycles followed by nivolumab monotherapy (3 mg/kg) fortnightly. Patient demographics and treatment parameters were collected and outcomes determined. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ajco.13100
Publisher Site
http://dx.doi.org/10.1111/ajco.13100DOI Listing
February 2019
16 Reads
1.060 Impact Factor

Prognostic significance of BRAF mutation alone and in combination with microsatellite instability in stage III colon cancer.

Asia Pac J Clin Oncol 2019 Feb 13;15(1):69-74. Epub 2018 Nov 13.

Department of Colorectal Surgery, Royal Adelaide Hospital, Adelaide, South Australia, Australia.

Purpose: The prognostic significance of biomarkers in colorectal cancer is still being defined. This study aimed to determine the prognostic significance of BRAF mutation alone and in combination with microsatellite instability (MSI), in stage III colon cancer.

Methods: Curatively resected stage III colon cancers were studied from a 33-year period. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ajco.13096
Publisher Site
http://dx.doi.org/10.1111/ajco.13096DOI Listing
February 2019
9 Reads

Association between PD-L1 expression and lymph node metastasis in cutaneous squamous cell carcinoma.

Asia Pac J Clin Oncol 2018 Nov 8. Epub 2018 Nov 8.

Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan.

Aim: To clarify the relationship between programmed cell death ligand 1 (PD-L1) expression in cutaneous squamous cell carcinoma (cSCC) and clinicopathological variables.

Methods: We examined PD-L1 expression in tumor cells (TCs) and tumor infiltrating immune cells (ICs) in 46 cases of cSCC by immunohistochemistry. In each case, we employed two methods-intensity and proportion scores-to evaluate PD-L1 expression in TCs. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ajco.13102
Publisher Site
http://dx.doi.org/10.1111/ajco.13102DOI Listing
November 2018
10 Reads

Favorable 10-year outcomes of image-guided intensity-modulated radiotherapy combined with long-term androgen deprivation for Japanese patients with nonmetastatic prostate cancer.

Asia Pac J Clin Oncol 2019 Feb 8;15(1):18-25. Epub 2018 Nov 8.

Department of Radiation Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.

Aim: To investigate 10-year outcomes of high-dose image-guided intensity-modulated radiation therapy (IG-IMRT) combined with long-term androgen deprivation therapy (ADT) for Japanese patients with nonmetastatic prostate cancer.

Methods: A retrospective analysis was performed on 208 Japanese patients with T1-4N0M0 prostate cancer, who underwent definitive IG-IMRT from 2006 to 2010 at our single institution. The median dose was 78 Gy (74-78) and median ADT time was 32 months (6-151). Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ajco.13097
Publisher Site
http://dx.doi.org/10.1111/ajco.13097DOI Listing
February 2019
15 Reads

PROGRAM IN DETAIL.

Authors:

Asia Pac J Clin Oncol 2018 Nov;14 Suppl 7:25-49

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13087DOI Listing
November 2018
1 Read

INTERNATIONAL SPEAKERS.

Authors:

Asia Pac J Clin Oncol 2018 Nov;14 Suppl 7:7-8

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ajco.13083
Publisher Site
http://dx.doi.org/10.1111/ajco.13083DOI Listing
November 2018
10 Reads

NATIONAL SPEAKERS.

Authors:

Asia Pac J Clin Oncol 2018 Nov;14 Suppl 7:9-20

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13084DOI Listing
November 2018
1 Read

FLOOR PLAN.

Authors:

Asia Pac J Clin Oncol 2018 Nov;14 Suppl 7:213

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13091DOI Listing
November 2018
1 Read

CONVENOR'S WELCOME 2018.

Authors:

Asia Pac J Clin Oncol 2018 Nov;14 Suppl 7

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13080DOI Listing
November 2018
1 Read

SPONSORS ACKNOWLEDGEMENTS.

Authors:

Asia Pac J Clin Oncol 2018 Nov;14 Suppl 7:24

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13085DOI Listing
November 2018
1 Read

EXHIBITOR LISTING.

Authors:

Asia Pac J Clin Oncol 2018 Nov;14 Suppl 7:214

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13092DOI Listing
November 2018
1 Read

COSA COMMITTEES.

Authors:

Asia Pac J Clin Oncol 2018 Nov;14 Suppl 7:3-4

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13081DOI Listing
November 2018
1 Read

COSA PRESIDENT'S WELCOME.

Authors:

Asia Pac J Clin Oncol 2018 Nov;14 Suppl 7

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13079DOI Listing
November 2018
1 Read

PROGRAMAT A GLANCE.

Authors:

Asia Pac J Clin Oncol 2018 Nov;14 Suppl 7:21-23

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13086DOI Listing
November 2018
1 Read

2018 COSA ASM EXHIBITOR PROFILES.

Authors:

Asia Pac J Clin Oncol 2018 Nov;14 Suppl 7:215-218

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13093DOI Listing
November 2018
1 Read

HIGHLIGHTED LECTURES AND AWARDS 2018.

Authors:

Asia Pac J Clin Oncol 2018 Nov;14 Suppl 7:5-6

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13082DOI Listing
November 2018
1 Read